Live Breaking News & Updates on Epcoritamab Epkinly Tepkinly

Stay updated with breaking news from Epcoritamab epkinly tepkinly. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

FDA Grants Priority Review to Epcoritamab-bysp for Relapsed or Refractory Follicular Lymphoma

If approved, epcoritamab (DuoBody CD3xCD20; AbbVie, Genmab) would be the first and only subcutaneous bispecific antibody for treatment in this patient population. ....

United States , Epcoritamab Epkinly Tepkinly , Epcoritamab Duobody , Mariana Cota Stirner , European Medicines Agency , Exposition Of The American Society Hematology , Drug Administration , Cota Stirner , Annual Meeting , American Society , Drug Administration Grants Priority Review , Difficult To Treat Relapsed , Refractory Follicular Lymphoma , Bispecific Antibody Epcoritamab , Shows Strong , Durable Treatment Response , Follicular Lymphoma , Refractory Follicular ,